US · Health Care
REGN stock analysis: filings, institutional holders, and operating trends
Regeneron Pharmaceuticals operates in the Biotechnology industry within the Health Care sector and is a constituent of the S&P 500. This page connects filing evidence with ownership, insider activity, forecasts, ETFs, and peer context so each dataset can be checked against the others.
Deterministic, source-linked commentary
What the latest evidence says about REGN
REGN's current operating picture begins with the latest company report. 10-Q covers CY2026Q1. quarterly revenue was $3.6B; year-over-year growth was 19.0%; operating margin was 17.8%; trailing free cash flow was $3.9B. Read together, these figures test whether scale is translating into profit and cash. Verify periods and company footnotes in the original SEC EDGAR filing.
REGN's published outlook is useful only while its inputs hold. The forecast scenarios were updated 2026-05-21. Revenue growth, margins, cash generation, and risk assumptions must be checked against each new filing.
The useful next step is to test REGN from another angle. Use institutional ownership, insider filings, forecast scenarios alongside the filing. Company facts can update before 13F positions, so align every source date and report period before treating a difference as a change in fundamentals.
Business model
Company snapshot
Regeneron Pharmaceuticals operates in the Biotechnology industry within the Health Care sector and is a constituent of the S&P 500. The latest standardized snapshot records $14.06B of trailing revenue, $4.97B of net income, and $3.86B of free cash flow. These figures describe the reported company, while valuation and price require a separate market-data timestamp.
Operating lines
A named product, service, or operating exposure identified in the company description.
A named product, service, or operating exposure identified in the company description.
Geographic revenue mix
The current standardized filing dataset does not extract a comparable geographic revenue table for every issuer. Review the latest 10-K segment note for domestic and international mix, concentration, foreign-exchange sensitivity, and country-specific regulation.
10-Q · 2026-04-29
What the latest filing shows
Revenue for the latest standardized quarter was $3.61B, while diluted EPS was 6.75. Revenue changed 19% from the comparable period. Gross margin was 98.1% and operating margin was 17.8%. Margin direction matters because it shows whether growth is translating into operating leverage or requiring more cost to support.
Open original SEC filingCY2026Q1
Earnings analysis
| Period | Revenue | Net income | EPS | Operating margin |
|---|---|---|---|---|
| CY2026Q1 | $3.61B | $727.2M | 6.75 | 17.8% |
| TTM | $14.06B | $4.97B | 40.45 | 23.8% |
| CY2025 | $14.34B | $4.5B | See filing | 24.9% |
The standardized data shows revenue growth of 19%, an operating margin of 23.8%, and a net margin of 35.3%. Without a dedicated earnings article, the original filing remains the primary source for management guidance and expectation comparisons.
Scenario analysis
Forecast range
REGN is a NASDAQ-100 stock with a checked price of 649.76, market cap of 66.11B, and revenue of 14.92B. A practical 2026 scenario map is $487-585 in a bear case, $598-747 in a base case, and $767-942 in a bull case. The forecast depends on healthcare innovation, product cycle, reimbursement, and pipeline execution.
Forecast assumptions
- Revenue growth must be checked against the latest filing and management guidance.
- Current reported operating margin is 23.8%.
- TTM free-cash-flow margin is 27.4%.
- Discount rates and valuation multiples should move when risk-free rates, business risk, or estimate confidence changes.
This is not a buy or sell recommendation. Forecasts are conditional ranges whose assumptions can fail.
Open forecast methodology and scenariosHealth Care
Peer comparison
| Company | TTM revenue | Revenue growth | Operating margin | Tracked holders |
|---|---|---|---|---|
| REGNRegeneron Pharmaceuticals | $14.06B | 19% | 23.8% | 0 |
| VTRSViatris | $14.07B | 8.2% | -18.1% | 0 |
| LHLabcorp | $13.97B | 5.8% | 10.7% | 0 |
| DVADaVita | $13.44B | 6% | 14.6% | 1 |
| HSICHenry Schein | $13.12B | 6.3% | 5.1% | 0 |
| IQVIQVIA | $16.1B | 8.4% | 12.9% | 0 |
| VRTXVertex Pharmaceuticals | $11.8B | 7.8% | 34.8% | 0 |
REGN's 19% revenue growth and 23.8% operating margin should be read against peers using the same reporting definitions. A higher margin may reflect pricing power or business mix, while a lower margin can reflect investment, cyclicality, or weaker economics.
10-K · 2026-02-04
Key risk factors disclosed in the latest 10-K
The categories below are a deterministic research checklist anchored to Regeneron Pharmaceuticals's industry and latest annual filing. They summarize areas investors should locate in Item 1A; they do not replace the company's exact legal disclosure.
- Demand and product-cycle risk: Biotechnology can experience changing customer demand, replacement cycles, and competitive product launches that affect revenue timing.
- Competition and execution: Market share depends on product quality, pricing, distribution, innovation, and management's ability to convert investment into durable customer demand.
- Supply chain and counterparties: Supplier concentration, logistics disruption, component availability, and customer concentration can affect delivery schedules, costs, and working capital.
- Regulation and litigation: Antitrust, privacy, securities, labor, tax, environmental, and industry-specific rules may change costs or restrict products and business practices.
- Financial and market risk: Foreign exchange, interest rates, credit conditions, investment values, and capital-allocation decisions can affect reported earnings and valuation.
Shareholder returns
Dividend and buyback history
Dividend
Regeneron Pharmaceuticals reported $285.4M of dividends paid over the trailing period and $97.8M in the latest standardized quarter. These are company cash outflows, not a per-share forward yield.
Share buybacks
The standardized snapshot does not currently expose a reliable repurchase authorization and share-count bridge for every issuer. Compare diluted shares outstanding across filings and read the capital-return note before concluding that buybacks reduced the share base.
Research workflow
Common research questions about REGN
Who is the largest tracked institutional holder of REGN?
The current tracked-manager sample does not identify an active REGN holder. The REGN ownership page will reflect a matching position when one enters the filing dataset.
What does recent insider activity show for REGN?
No recent Form 4 transaction appears in the current REGN window. Check the REGN Form 4 history for later company-officer or director filings.
What business does Regeneron Pharmaceuticals operate?
Regeneron Pharmaceuticals operates in the Biotechnology industry within the Health Care sector and is a constituent of the S&P 500. The REGN company snapshot connects that business description with reported revenue, profit, and cash flow.
How does REGN compare with a close operating peer?
REGN's revenue growth is 19.0% and its operating margin is 23.8%. Compare those figures with VTRS research using the same definitions.
What do the latest financials say about REGN?
10-Q reports $14.1B of trailing revenue, with revenue growth of 19.0% and an operating margin of 23.8%. The supporting period and source are listed in the REGN filing section.
How strong is REGN's cash return profile?
Regeneron Pharmaceuticals reported $285.4M of trailing dividends paid alongside $3.9B of free cash flow. The REGN capital-return section separates company cash outflows from a forward per-share yield.
Which assumptions matter most for the REGN outlook?
The REGN range depends on revenue growth, operating margin, cash conversion, and the risk assumptions in each new filing. Recheck them in the REGN forecast section.
Primary and reference data
Sources and methodology
- Filings: SEC EDGAR CompanyFacts, 10-K, 10-Q, 8-K, Form 4, 13F-HR.
- Fundamentals: SEC EDGAR CompanyFacts; market references may use yfinance and Finnhub where explicitly available.
- ETF: Issuer disclosures and the locally dated ETF holdings snapshot.
Methodology: How SnowballHare parses and validates data.
Editorial standards: How research is published.
Disclaimer: Informational only; not investment, legal, or tax advice. Cross-check material facts against original filings before acting.
Reference notes
Data notes
Reporting dates
Use filing dates, report periods, and source links together for REGN. A company filing, a 13F disclosure, a Form 4 transaction, and an earnings release can describe different time windows, so the date beside each row matters before comparing signals.
Ownership context
13F rows are delayed public long-equity snapshots from a selected manager universe. They are useful for seeing which tracked institutions reported exposure, but they do not show every hedge, short position, cash balance, or trade made after the quarter ended.
Insider transactions
Form 4 activity should be read by transaction type, role, value, and remaining ownership. Open-market purchases and sales are different from grants, option exercises, gifts, or tax withholding, and the original SEC filing is still the controlling document.
Earnings and forecasts
Earnings pages and forecast pages are linked when a supported article exists. Treat those pages as context for reported numbers, guidance, margins, and scenario assumptions, then return to the table data when you need the underlying source date or filing trail.